-
81.发明授权公开(公告)号：US08048416B2
公开(公告)日：2011-11-01
申请号：US11786165
申请日：2007-04-11
IPC分类号： A61K39/395 , A61K39/44
CPC分类号： C07K16/30 , A61K47/6849 , A61K49/0013 , A61K2039/505 , C07K16/2884 , C07K2317/24 , G01N33/574 , G01N33/57492 , G01N2333/70585
摘要： This invention relates to the diagnosis and treatment of cancerous diseases, particularly to the mediation of cytotoxicity of primary and metastatic human tumor cells; and most particularly to the use of an isolated monoclonal antibody or cancerous disease modifying antibodies (CDMAB) thereof, optionally in combination with one or more chemotherapeutic agents, as a means for initiating the cytotoxic response in human tumors, e.g. any primary or metastatic tumor sites which arise from hepatocytes and to binding assays which utilize the CDMAB of the instant invention.
摘要翻译： 本发明涉及癌性疾病的诊断和治疗，特别涉及原发性和转移性人类肿瘤细胞的细胞毒性的介导; 并且最特别地涉及使用分离的单克隆抗体或其改变其抗癌（CDMAB）的抗体（CDMAB），任选地与一种或多种化学治疗剂组合，作为在人肿瘤中引发细胞毒性应答的手段，例如。 由肝细胞产生的任何原发性或转移性肿瘤部位和利用本发明的CDMAB的结合试验。
-
公开(公告)号：US06657048B2
公开(公告)日：2003-12-02
申请号：US09727361
申请日：2000-11-29
IPC分类号： C07K1600
CPC分类号： C07K16/00 , A61K2039/505 , C07K16/30 , C07K2317/73 , G01N33/57484 , G01N33/6854 , G01N2500/00
摘要： The present invention relates to a method for producing patient specific anti-cancer antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the production of anti-cancer antibodies customized for the individual patient that can be used for therapeutic and diagnostic purposes. The invention further relates to the process by which the antibodies are made and to their methods of use. The antibodies can be made specifically for one tumor derived from a particular patient and are selected on the basis of their cancer cell cytotoxicity and simultaneous lack of toxicity for non-cancerous cells. The antibodies can be used in aid of staging and diagnosis of a cancer, and can be used to treat tumor metastases. The anti-cancer antibodies can be conjugated to red blood cells obtained from that patient and re-infused for treatment of metastases based upon the recognition that metastatic cancers are usually well vascularized and the delivery of anti-cancer antibodies by red blood cells can have the effect of concentrating the antibodies at the site of the tumor.
-
83.发明申请公开(公告)号：US20120020880A1
公开(公告)日：2012-01-26
申请号：US13243870
申请日：2011-09-23
IPC分类号： A61K39/395 , A61P35/00 , A61K51/00
CPC分类号： C07K16/30 , A61K47/6849 , A61K49/0013 , A61K2039/505 , C07K16/2884 , C07K2317/24 , G01N33/574 , G01N33/57492 , G01N2333/70585
摘要： This invention relates to the diagnosis and treatment of cancerous diseases, particularly to the mediation of cytotoxicity of primary and metastatic human tumor cells; and most particularly to the use of an isolated monoclonal antibody or cancerous disease modifying antibodies (CDMAB) thereof, optionally in combination with one or more chemotherapeutic agents, as a means for initiating the cytotoxic response in such human tumors, e.g. any primary or metastatic tumor sites which arise from hepatocytes. The invention further relates to binding assays which utilize the CDMAB of the instant invention.
摘要翻译： 本发明涉及癌性疾病的诊断和治疗，特别涉及原发性和转移性人类肿瘤细胞的细胞毒性的介导; 并且最特别地涉及使用分离的单克隆抗体或其改变其抗癌（CDMAB）的抗体（CDMAB），任选地与一种或多种化学治疗剂组合，作为在这样的人类肿瘤中起始细胞毒性应答的手段。 任何由肝细胞产生的原发性或转移性肿瘤部位。 本发明还涉及利用本发明的CDMAB的结合测定法。
-
公开(公告)号：US07256272B2
公开(公告)日：2007-08-14
申请号：US10713642
申请日：2003-11-13
IPC分类号： C07K16/00 , C12P21/08 , A61K39/395 , A61K39/00
CPC分类号： C07K16/00 , A61K2039/505 , C07K16/30 , C07K2317/73 , G01N33/57484 , G01N33/6854 , G01N2500/00
摘要： The present invention relates to a method for producing patient specific anti-cancer antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the production of anti-cancer antibodies customized for the individual patient that can be used for therapeutic and diagnostic purposes. The invention further relates to the process by which the antibodies are made and to their methods of use. The antibodies can be made specifically for one tumor derived from a particular patient and are selected on the basis of their cancer cell cytotoxicity and simultaneous lack of toxicity for non-cancerous cells.
摘要翻译： 本发明涉及使用新的筛选范例来生产患者特异性抗癌抗体的方法。 通过使用癌细胞细胞毒性分离抗癌抗体作为终点，该方法使得可以为可用于治疗和诊断目的的个体患者定制抗癌抗体。 本发明还涉及制备抗体的方法及其使用方法。 抗体可以专门针对来自特定患者的一种肿瘤进行制备，并且基于它们的癌细胞细胞毒性和对非癌细胞同时缺乏毒性进行选择。
-
-
-
搜索结果
84 条记录 (耗时 0.028 秒)
